Medicines Australia calls for trial improvements

Trade group Medicines Australia has published a paper calling for improvements to be made to clinical trials.

Such changes will help the country’s biopharmaceutical sector to become more competitive globally, according to the group, which stressed that clinical trials provide benefits to patients, the healthcare system and the economy.

"Each state and territory have different regulatory and ethics approval systems. In Australia, that creates a delay and a barrier to setting up and recruiting patients"Medicines Australia cited the events of the COVID-19 pandemic as evidence of how quickly innovative medicines, therapeutics and vaccines can evolve and argued that encouraging the global biopharmaceutical industry to invest in Australian clinical trials creates highly-skilled jobs, a more competitive economy and puts patients at the front of the queue for innovative treatments.